Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.8 million people in the United States (naaf.org), with a worldwide prevalence of 0.1% to 0.2%. AA and its variants such as alopecia totalis (AT, total loss of scalp hair) and alopecia universalis (AU, complete loss of body hair) can have devastating effects on patients’ quality of life and social functioning. At present, curative therapy for AA does not exist.
Tianhe has developed a novel globally-patented Stem Cell Educator (SCE) technology designed to reverse the autoimmune response in Type 1 diabetes (T1D), Alopecia Areata and other autoimmune diseases. Previous clinical trial demonstrated the safety and efficacy of the SCE therapy for the treatment of AA and produced lasting improvement in hair regrowth in subjects with moderate or severe AA. Currently, this FDA-approved Phase 2 clinical study will be performed at Hackensack University Medical Center and Department of Dermatology/School of Medicine at Yale University. For more information, please contact info@TianheCell.com